Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluation of the Aspheric ReSTOR Intraocular Lens (IOL) After Routine Cataract Extraction
This study has been completed.
Sponsored by: Medical University of South Carolina
Information provided by: Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT00565695
  Purpose

The purpose of this study is to evaluate the visual outcomes and patient satisfaction after bilateral implantation of the aspheric ReSTOR multifocal intraocular lens (IOL) and compare it to a historical control group of patients implanted bilaterally with the spherical ReSTOR multifocal IOL.


Condition Intervention
Cataract Extraction
Refractive Surgery
Device: aspheric ReSTOR multifocal intraocular lens (IOL)
Device: Aspheric ReSTOR multifocal intraocular lens (IOL)

MedlinePlus related topics: Cataract
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Efficacy Study
Official Title: Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction

Further study details as provided by Medical University of South Carolina:

Estimated Enrollment: 20
Study Start Date: October 2007
Study Completion Date: September 2008
Intervention Details:
    Device: aspheric ReSTOR multifocal intraocular lens (IOL)
    Multi
    Device: Aspheric ReSTOR multifocal intraocular lens (IOL)
    Mulitfocal Intraocular Lens
Detailed Description:

Cataract is prevalent throughout the world and IOLs are routinely implanted after the extraction of the cataractous lens. It is the most frequently performed surgery in the United States with an estimated 2-3 million procedures performed annually. With the aging population on the rise, as well as the increasing popularity of refractive intraocular lenses, the number of intraocular surgeries continues to rise. Over the years, the surgical technique has evolved from intracapsular extraction to modern phacoemulsification. This development has helped with the evolution of IOLs as well. The IOLs have advanced extensively: different materials and designs are available, permitting implantation through smaller, sutureless incisions. Traditional IOLs are of monofocal design providing vision at one distance, typically far. Patients implanted with traditional monofocal IOLs usually require glasses for near distance tasks such as reading. The new multifocal IOLs offer the possibility of seeing well at more than one distance, without glasses or contacts. The AcrySof ReSTOR (Alcon Laboratories) uses apodized diffractive technology — a design that responds to how wide or small the eye's pupil might be — to provi de near, intermediate, and distance vision. Clinical studies used to support the March 2005 FDA approval showed that 80% of people who received the lens did not use glasses for any activities after their cataract surgery; 84% who received the lens in both eyes had distance vision of 20/25 or better, with near vision of 20/32 or better. Wavefront analysis is a technique currently used to measure the aberrations of the entire optical system. The term aberration derives from the Latin ab-erratio, which means going offtrack or deviating. Therefore, and aberration is the difference that exists between the ideal image of that we would expect to see when the luminous rays are refracted in the perfect optical system (Snell's law) and what is actually achieved. This technology is widely used in refractive surgery with successful outcomes. With the introduction of wavefront analysis, a new tool is available to re-design and study the performance of IOLs. Regarding IOL design, it has been used to modify the IOL to partially compensate for the average spherical aberration. The goal is to improve the ocular optical quality of pseudophakic patients. Clinical results using the aspheric monofocal IOLs confirm that this modification leads to a significant improvement, particularly in contrast sensitivity, mesopic visual quality and reduction of high order aberrations mainly spherical aberration when compare to spherical IOLs. The new aspheric ReSTOR IOL is the first single piece acrylic multifocal IOL to be available in the United States and a comparison to a regular (spherical) multifocal IOL is necessary to determine if the aspheric ReSTOR lens shows the same improvement.

The purpose of this study is to evaluate the visual outcomes and patient satisfaction after bilateral implantation of the aspheric ReSTOR multifocal intraocular lens (IOL) and compare it to a historical control group of patients implanted bilaterally with the spherical ReSTOR multifocal IOL.

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects MUST fulfill the following conditions to qualify for enrollment into the trial
  • Subject must have an age-related cataract in both eyes.
  • 40 years of age or older.
  • Patient must desire cataract extraction.
  • Expected maximum of 2 weeks and minimum of 1-week interval between first and second eye surgeries.
  • Willing and able to comply with scheduled visits and other study procedures.

Exclusion Criteria:

  • Preoperative ocular pathology:

    • Amblyopia
    • Rubella cataract
    • Proliferative diabetic retinopathy
    • Shallow anterior chamber
    • Macular edema
    • Retinal detachment
    • Aniridia or iris atrophy
    • Uveitis
    • History of iritis
    • Iris neovascularization
    • Medically uncontrolled glaucoma
    • Microphtalmus or macrophtalmus
    • Optic nerve atrophy
    • Macular degeneration (with anticipated best postoperative visual acuity less than 20/30)
    • Advanced glaucomatous damage, etc.
  • Keratometric astigmatism exceeding 1.50 diopters.
  • Planned postoperative refraction for mono-vision.
  • Uncontrolled diabetes.
  • Use of any systemic or topical drug known to interfere with visual performance.
  • Contact lens use during the active treatment portion of the trial.
  • Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis.
  • Pregnant or nursing mothers and females of childbearing potential not practicing a reliable and medically acceptable method of birth control.
  • Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or study device
  • implantation or may interfere with the interpretation of study results.
  • Participation in (or current participation) any investigational drug or device trialwithin the previous 30 days prior to the start date of this trial.
  • Intraocular conventional surgery within the past three months or intraocular laser surgery within one month in the operated eye.
  • Other ocular surgery at the time of the cataract extraction.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00565695

Locations
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Investigators
Principal Investigator: Kerry D Solomon, MD Medical University of South Carolina, Storm Eye Institute
  More Information

Study ID Numbers: SEI-07-002
Study First Received: November 29, 2007
Last Updated: October 3, 2008
ClinicalTrials.gov Identifier: NCT00565695  
Health Authority: United States: Institutional Review Board

Keywords provided by Medical University of South Carolina:
Visual Outcomes
Patient Satisfaction
Cataract Extraction

Study placed in the following topic categories:
Eye Diseases
Cataract
Lens Diseases

ClinicalTrials.gov processed this record on January 15, 2009